Main menu

Tag: Amsbio

A clinical grade stem cell culture for regenerative medicine, StemFit Basic03, has been launched by Amsbio. Provided ready to use from an animal-origin free, the StemFit Basic03 medium provides stable and reproducible culture condition for induced pluripotent stem and embryonic…

Researchers in Barcelona report progress in the use of 3D organoid technology to create an analogue of human colon cancer in a mouse model. The study, from the Institute for Research in Biomedicine (IRB), shows that the hormone (transforming growth…

AN EXPANDED catalogue of primary and progenitor cell types and media with a new range of human endothelial progenitor cells (EPC) has been announced by Amsbio. These human EPCs are derived from bone marrow and have properties similar to embryonic…

A RANGE of progenitor cells derived from healthy mouse small intestine tissue will be of particular interest to research groups using BME 2 organoid matrix and specialising in drug screening applications, says Amsbio. The company has extended its product range…

MAGNETIC bead technology has been applied in various laboratory activities, often bringing advantages in terms of speed and convenience when separating samples into compounds of interest. Amsbio says its new MagSi-DNA Vegetal kit brings the convenience and cost effectiveness of…

ZIKA virus is presently causing significant worldwide concern due its rapid spread across the globe and suggested connection to a neurological birth disorder. The outbreak began in Brazil in 2015 and has since spread throughout South and Central America, and…

CRISPR/Cas gene editing is a relatively new technique which offers high accuracy in gene targeting and better target sequence selection, with less complexity and less off-target toxicity than previous genome editing technologies. Amsbio provides a standalone premade Cas9 expression lentivirus,…

THE latest developments in extracellular matrix (ECM) and the opportunities they offer in cancer research are discussed in a new white paper from Amsbio. At least 80 percent of cancers are carcinomas, or tumours of the epithelia. Traditionally, cell transformation…

AMSBIO says there is a growing need for more complete and physiologically predictive cancer invasion models, and so has launched its new 3D Culture 96-Well BME cell invasion assay to address this. The BME (basement membrane extract) assay offers a…

A NEW range of human feeder cells from Amsbio are qualified for induced Pluripotent Stem Cell (iPSC) reprogramming. These newborn human foreskin fibroblasts, available under the trade name NuFF-RQ, are validated to support iPSC colony generation, providing an optimised feeder…